Payment overview · 2025
General Payments
$117.26
6 reported records · 5 companies
Healthcare provider profile · identity verified
Lynn Q Beard, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WILLARD, UT · NPI 1679502801
Verified facts
What the public records show
CMS Open Payments records show Lynn Q Beard, M.D. received $117.26 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 42.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.37 | 42.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.73 | 16.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.73 | 14.3% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $15.96 | 13.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.47 | 13.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $117.26 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.37 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 853 | 246 |
| Omeprazole | Omeprazole | 487 | 155 |
| Lisinopril | Lisinopril | 364 | 109 |
| Losartan Potassium | Losartan Potassium | 304 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 296 | 48 |
| Metformin Hcl | Metformin Hcl | 289 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 287 | 68 |
| Tramadol Hcl | Tramadol Hcl | 273 | 48 |
| Gabapentin | Gabapentin | 231 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 61 |
| Meloxicam | Meloxicam | 203 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 57 |
| Lorazepam | Lorazepam | 162 | 31 |
| Trazodone Hcl | Trazodone Hcl | 161 | 41 |
| Clonazepam | Clonazepam | 154 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 150 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 150 | 24 |
| Potassium Chloride | Potassium Chloride | 137 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 128 | 41 |
| Farxiga | Dapagliflozin Propanediol | 125 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 112 | 35 |
| Furosemide | Furosemide | 110 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 29 |
| Eliquis | Apixaban | 103 | 30 |
| Alprazolam | Alprazolam | 101 | 19 |
| Mounjaro | Tirzepatide | 100 | 17 |
| Alendronate Sodium | Alendronate Sodium | 87 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 22 |
| Xarelto | Rivaroxaban | 75 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 22 |
| Ozempic | Semaglutide | 72 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 16 |
| Trulicity | Dulaglutide | 66 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 65 | 21 |
| Glipizide | Glipizide | 64 | 17 |
| Sertraline Hcl | Sertraline Hcl | 63 | 20 |
| Spironolactone | Spironolactone | 63 | 16 |
| Finasteride | Finasteride | 61 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 30 |
| Allopurinol | Allopurinol | 58 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 16 |
| Diazepam | Diazepam | 58 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 17 |
| Carvedilol | Carvedilol | 56 | 13 |
| Jardiance | Empagliflozin | 56 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 32 |
| Prednisone | Prednisone | 54 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 51 | 13 |
| Bupropion Xl | Bupropion Hcl | 48 | 15 |
| Estradiol | Estradiol | 45 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 14 |
| Ezetimibe | Ezetimibe | 40 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 26 |
| Aripiprazole | Aripiprazole | 34 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 22 |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 15 |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 15 |
| Famotidine | Famotidine | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $117.26 · 6 records | ABBVIE INC. | AREXVY, ENTRESTO, LEQVIO, OTEZLA, REPATHA, SHINGRIX, SUBLOCADE, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error